<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38485476</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>14</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Subphenotypes of self-reported symptoms and outcomes in long COVID: a prospective cohort study with latent class analysis.</ArticleTitle><Pagination><StartPage>e077869</StartPage><MedlinePgn>e077869</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e077869</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2023-077869</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To characterise subphenotypes of self-reported symptoms and outcomes (SRSOs) in postacute sequelae of COVID-19 (PASC).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective, observational cohort study of subjects with PASC.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Academic tertiary centre from five clinical referral sources.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Adults with COVID-19 &#x2265;20 days before enrolment and presence of any new self-reported symptoms following COVID-19.</AbstractText><AbstractText Label="EXPOSURES" NlmCategory="METHODS">We collected data on clinical variables and SRSOs via structured telephone interviews and performed standardised assessments with validated clinical numerical scales to capture psychological symptoms, neurocognitive functioning and cardiopulmonary function. We collected saliva and stool samples for quantification of SARS-CoV-2 RNA via quantitative PCR.</AbstractText><AbstractText Label="OUTCOMES MEASURES" NlmCategory="METHODS">Description of PASC SRSOs burden and duration, derivation of distinct PASC subphenotypes via latent class analysis (LCA) and relationship with viral load.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We analysed baseline data for 214 individuals with a study visit at a median of 197.5 days after COVID-19 diagnosis. Participants reported ever having a median of 9/16 symptoms (IQR 6-11) after acute COVID-19, with muscle-aches, dyspnoea and headache being the most common. Fatigue, cognitive impairment and dyspnoea were experienced for a longer time. Participants had a lower burden of active symptoms (median 3 (1-6)) than those ever experienced (p&lt;0.001). Unsupervised LCA of symptoms revealed three clinically active PASC subphenotypes: a high burden constitutional symptoms (21.9%), a persistent loss/change of smell and taste (20.6%) and a minimal residual symptoms subphenotype (57.5%). Subphenotype assignments were strongly associated with self-assessments of global health, recovery and PASC impact on employment (p&lt;0.001) as well as referral source for enrolment. Viral persistence (5.6% saliva and 1% stool samples positive) did not explain SRSOs or subphenotypes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We identified three distinct PASC subphenotypes. We highlight that although most symptoms progressively resolve, specific PASC subpopulations are impacted by either high burden of constitutional symptoms or persistent olfactory/gustatory dysfunction, requiring prospective identification and targeted preventive or therapeutic interventions.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kitsios</LastName><ForeName>Georgios D</ForeName><Initials>GD</Initials><Identifier Source="ORCID">0000-0002-1018-948X</Identifier><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA kitsiosg@upmc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Medicine and the Microbiome, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blacka</LastName><ForeName>Shawna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Jana J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirza</LastName><ForeName>Taaha</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Internal Medicine Residency Program, UPMC in Central Pa, Harrisburg, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naqvi</LastName><ForeName>Asma</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gentry</LastName><ForeName>Heather</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Cathy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaohong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golubykh</LastName><ForeName>Konstantin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Internal Medicine Residency Program, UPMC in Central Pa, Harrisburg, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qurashi</LastName><ForeName>Hafiz</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dodia</LastName><ForeName>Akash</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Risbano</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benigno</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pfizer Inc, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emir</LastName><ForeName>Birol</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Pfizer Inc, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinstein</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pfizer Inc, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bramson</LastName><ForeName>Candace</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pfizer Inc, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Lili</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pfizer Inc, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Pfizer Inc, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szigethy</LastName><ForeName>Eva</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-6783-581X</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mellors</LastName><ForeName>John W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Methe</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Medicine and the Microbiome, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sciurba</LastName><ForeName>Frank C</ForeName><Initials>FC</Initials><Identifier Source="ORCID">0000-0001-7468-2225</Identifier><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emphysema Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nouraie</LastName><ForeName>Seyed Mehdi</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0001-7465-0581</Identifier><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Medicine and the Microbiome, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057566" MajorTopicYN="N">Self Report</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077272" MajorTopicYN="N">Latent Class Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004417" MajorTopicYN="N">Dyspnea</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">respiratory infections</Keyword><Keyword MajorTopicYN="N">virology</Keyword></KeywordList><CoiStatement>Competing interests: GDK has received research funding from Karius and Genentech, unrelated to this work. GDK, AM, JM, FCS and SMN have received funding from Pfizer.JWM is a consultant to Gilead Sciences, Inc. and has received grant funding from Gilead Sciences, Inc., to the University of Pittsburgh; receives compensation from Galapagos NV; and, holds share options in Galapagos NV, Infectious Disease Connect, Inc., and MingMed Biotechnology Co., Ltd., all unrelated to the current work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>15</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>14</Day><Hour>22</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38485476</ArticleId><ArticleId IdType="pmc">PMC10941166</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2023-077869</ArticleId><ArticleId IdType="pii">bmjopen-2023-077869</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. . Post-acute COVID-19 syndrome. Nat Med 2021;27:601&#x2013;15. 10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahoney LL, Routen A, Gillies C, et al. . The prevalence and long-term health effects of long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine 2023;55:101762. 10.1016/j.eclinm.2022.101762</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101762</ArticleId><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T, Jolley SE, Karlson EW, et al. . Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA 2023;329:1934&#x2013;46. 10.1001/jama.2023.8823</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.8823</ArticleId><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballouz T, Menges D, Anagnostopoulos A, et al. . Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study. BMJ 2023;381:e074425. 10.1136/bmj-2022-074425</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-074425</ArticleId><ArticleId IdType="pmc">PMC10230608</ArticleId><ArticleId IdType="pubmed">37257891</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH, Santillana M, Ognyanova K, et al. . Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open 2022;5:e2238804. 10.1001/jamanetworkopen.2022.38804</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.38804</ArticleId><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvakumar J, Havdal LB, Drevvatne M, et al. . Prevalence and characteristics associated with post-COVID-19 condition among nonhospitalized adolescents and young adults. JAMA Netw Open 2023;6:e235763. 10.1001/jamanetworkopen.2023.5763</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.5763</ArticleId><ArticleId IdType="pmc">PMC10064252</ArticleId><ArticleId IdType="pubmed">36995712</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH, Lunz Trujillo K, Safarpour A, et al. . Association of post-COVID-19 condition symptoms and employment status. JAMA Netw Open 2023;6:e2256152. 10.1001/jamanetworkopen.2022.56152</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.56152</ArticleId><ArticleId IdType="pmc">PMC9932847</ArticleId><ArticleId IdType="pubmed">36790806</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. Nat Med 2023;29:2347&#x2013;57. 10.1038/s41591-023-02521-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02521-2</ArticleId><ArticleId IdType="pmc">PMC10504070</ArticleId><ArticleId IdType="pubmed">37605079</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, et al. . Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023;21:133&#x2013;46. 10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki A, Putrino D. Why we need a deeper understanding of the pathophysiology of long COVID. Lancet Infect Dis 2023;23:393&#x2013;5. 10.1016/S1473-3099(23)00053-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00053-1</ArticleId><ArticleId IdType="pmc">PMC9928485</ArticleId><ArticleId IdType="pubmed">36967698</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB, Aleman S, et al. . SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). Nat Immunol 2023;24:1616&#x2013;27. 10.1038/s41590-023-01601-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01601-2</ArticleId><ArticleId IdType="pubmed">37667052</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J, Wood J, Jaycox JR, et al. . Distinguishing features of long COVID identified through immune profiling. Nature 2023;623:139&#x2013;48. 10.1038/s41586-023-06651-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06651-y</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherif ZA, Gomez CR, Connors TJ, et al. . Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC). Elife 2023;12:e86002. 10.7554/eLife.86002</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.86002</ArticleId><ArticleId IdType="pmc">PMC10032659</ArticleId><ArticleId IdType="pubmed">36947108</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer RL, Kroenke K, Williams JBW, et al. . A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092&#x2013;7. 10.1001/archinte.166.10.1092</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.166.10.1092</ArticleId><ArticleId IdType="pubmed">16717171</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606&#x2013;13. 10.1046/j.1525-1497.2001.016009606.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1525-1497.2001.016009606.x</ArticleId><ArticleId IdType="pmc">PMC1495268</ArticleId><ArticleId IdType="pubmed">11556941</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastien CH, Valli&#xe8;res A, Morin CM. Validation of the insomnia severity index as an outcome measure for insomnia research. Sleep Med 2001;2:297&#x2013;307. 10.1016/s1389-9457(00)00065-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1389-9457(00)00065-4</ArticleId><ArticleId IdType="pubmed">11438246</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawes P, Pye A, Reeves D, et al. . Protocol for the development of versions of the Montreal cognitive assessment (Moca) for people with hearing or vision impairment. BMJ Open 2019;9:e026246. 10.1136/bmjopen-2018-026246</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2018-026246</ArticleId><ArticleId IdType="pmc">PMC6475249</ArticleId><ArticleId IdType="pubmed">30928949</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988;93:580&#x2013;6. 10.1378/chest.93.3.580</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.93.3.580</ArticleId><ArticleId IdType="pubmed">3342669</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs JL, Bain W, Naqvi A, et al. . Severe acute respiratory syndrome Coronavirus 2 Viremia is associated with Coronavirus disease 2019 severity and predicts clinical outcomes. Clin Infect Dis 2022;74:1525&#x2013;33. 10.1093/cid/ciab686</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab686</ArticleId><ArticleId IdType="pmc">PMC9070832</ArticleId><ArticleId IdType="pubmed">34374761</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs JL, Naqvi A, Shah FA, et al. . Plasma SARS-CoV-2 RNA levels as a biomarker of lower respiratory tract SARS-CoV-2 infection in critically ill patients with COVID-19. J Infect Dis 2022;226:2089&#x2013;94. 10.1093/infdis/jiac157</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac157</ArticleId><ArticleId IdType="pmc">PMC10205612</ArticleId><ArticleId IdType="pubmed">35511031</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha P, Calfee CS, Delucchi KL. Practitioner&#x2019;s guide to latent class analysis: methodological considerations and common pitfalls. Crit Care Med 2021;49:e63&#x2013;79. 10.1097/CCM.0000000000004710</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000004710</ArticleId><ArticleId IdType="pmc">PMC7746621</ArticleId><ArticleId IdType="pubmed">33165028</ArticleId></ArticleIdList></Reference><Reference><Citation>Department of Health and Human Services, Office of the Assistant Secretary for Health . National research action plan on long COVID, 200 Independence Ave SW. Washington, DC, 2021.</Citation></Reference><Reference><Citation>World Health&#xa0;Organization . A clinical case definition of post COVID-19 condition by a Delphi consensus. 2021.</Citation></Reference><Reference><Citation>Tan BKJ, Han R, Zhao JJ, et al. . Prognosis and persistence of smell and taste dysfunction in patients with COVID-19: meta-analysis with parametric cure modelling of recovery curves. BMJ 2022;378:e069503. 10.1136/bmj-2021-069503</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069503</ArticleId><ArticleId IdType="pmc">PMC9326326</ArticleId><ArticleId IdType="pubmed">35896188</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CJ-W, Tan BKJ, Tan XY, et al. . Neuroradiological basis of COVID-19 olfactory dysfunction: a systematic review and meta-analysis. Laryngoscope 2022;132:1260&#x2013;74. 10.1002/lary.30078</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.30078</ArticleId><ArticleId IdType="pmc">PMC9088641</ArticleId><ArticleId IdType="pubmed">35318656</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bartheld CS, Wang L. Prevalence of olfactory dysfunction with the Omicron variant of SARS-CoV-2: a systematic review and meta-analysis. Cells 2023;12:430. 10.3390/cells12030430</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12030430</ArticleId><ArticleId IdType="pmc">PMC9913864</ArticleId><ArticleId IdType="pubmed">36766771</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian V, Elghazaly H, Chattopadhyay R, et al. . Risk factors associated with post-COVID-19 condition: a systematic review and meta-analysis. JAMA Intern Med 2023;183:566&#x2013;80. 10.1001/jamainternmed.2023.0750</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0750</ArticleId><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopoorian A, Banada P, Reiss R, et al. . Persistence of SARS-CoV-2 in saliva: implications for late-stage diagnosis and infectious duration. PLoS ONE 2023;18:e0282708. 10.1371/journal.pone.0282708</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0282708</ArticleId><ArticleId IdType="pmc">PMC10019618</ArticleId><ArticleId IdType="pubmed">36928472</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>